MedTrace Logo

Octreotide Microspheres for Preventing Pancreatic Fistula

NCT07479784 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2026-03-18

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of octreotide microspheres in preventing pancreatic fistula after distal pancreatectomy.

Conditions

  • Pancreatic Fistula

Interventions

DRUG

Octreotide Microspheres

Octreotide Microspheres: 30mg, intramuscular injection, administered 7 days before surgery

DRUG

Placebo

Control group: Placebo (normal saline), administered 7 days before surgery.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2027-12-31
Completion
2028-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07479784 on ClinicalTrials.gov